Profile data is unavailable for this security.
About the company
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
- Revenue in SEK (TTM)11.23m
- Net income in SEK-16.40m
- Incorporated2014
- Employees2.00
- LocationElicera Therapeutics ABWorld Trade Center GoteborgMassans gata 10, van 7GOETEBORG 412 51SwedenSWE
- Websitehttps://www.elicera.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Circio Holding ASA | 123.02k | -110.76m | 18.50m | 11.00 | -- | -- | -- | 150.35 | -16.75 | -16.75 | 0.0181 | -12.89 | 0.0019 | -- | 0.0072 | 11,181.82 | -172.29 | -46.58 | -- | -53.40 | -- | -- | -90,029.27 | -6,902.00 | -- | -9.82 | 7.73 | -- | -98.77 | 35.43 | 74.42 | -- | -- | -- |
| Peptonic Medical AB | 37.12m | -42.59m | 18.73m | 38.00 | -- | 0.2486 | -- | 0.5045 | -0.0362 | -0.0362 | 0.0326 | 0.0491 | 0.3857 | 1.32 | -- | 976,789.50 | -44.25 | -46.02 | -67.60 | -60.85 | 43.90 | 54.26 | -114.74 | -139.38 | 0.7771 | -29.32 | 0.0912 | -- | -14.93 | 149.65 | -15.55 | -- | 14.43 | -- |
| Asarina Pharma AB (publ) | 0.00 | -12.91m | 21.46m | -- | -- | 13.73 | -- | -- | -0.5704 | -0.5704 | 0.00 | 0.069 | 0.00 | -- | -- | -- | -113.04 | -61.28 | -150.47 | -71.81 | -- | -- | -- | -- | -- | -- | 0.3902 | -- | -- | -- | 2.79 | -- | -- | -- |
| Cyxone AB | 0.00 | -22.99m | 22.13m | 4.00 | -- | 0.5681 | -- | -- | -0.1902 | -0.1902 | 0.00 | 0.1804 | 0.00 | -- | -- | -- | -47.81 | -66.19 | -53.03 | -72.35 | -- | -- | -- | -- | -- | -- | 0.0216 | -- | -- | -- | 45.87 | -- | -12.69 | -- |
| Lidds AB | 0.00 | -40.21m | 23.27m | 2.00 | -- | 0.837 | -- | -- | -0.7253 | -0.7253 | 0.00 | 0.2037 | 0.00 | -- | -- | 0.00 | -184.53 | -46.33 | -274.92 | -51.61 | -- | -- | -- | -3,076.68 | -- | -- | -- | -- | -100.00 | -- | -9.08 | -- | -- | -- |
| Redwood Pharma AB | 0.00 | -13.60m | 26.22m | 1.00 | -- | 0.3878 | -- | -- | -5.87 | -5.87 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -106.53 | -95.03 | -121.24 | -123.04 | -- | -- | -- | -- | -- | -19.12 | 0.00 | -- | -- | -- | -8.78 | -- | -5.11 | -- |
| Fluicell AB | 3.34m | -26.55m | 31.07m | 17.00 | -- | 26.05 | -- | 9.31 | -0.2201 | -0.2201 | 0.0282 | 0.0036 | 0.1624 | 0.6813 | 3.84 | 196,352.90 | -129.20 | -87.55 | -222.48 | -126.02 | 52.07 | 72.97 | -795.51 | -650.23 | 0.5001 | -- | 0.00 | -- | 2.68 | 22.18 | -22.90 | -- | -- | -- |
| Klaria Pharma Holding AB (publ) | 0.00 | -18.39m | 31.95m | 5.00 | -- | 0.7768 | -- | -- | -0.1824 | -0.355 | 0.00 | 0.3862 | 0.00 | -- | -- | 0.00 | -19.03 | -37.28 | -31.28 | -51.56 | -- | -- | -- | -2,077.34 | -- | -3.88 | 0.00 | -- | -100.00 | -- | 71.17 | -- | -- | -- |
| Elicera Therapeutics AB | 11.23m | -16.40m | 33.27m | 2.00 | -- | 1.14 | -- | 2.96 | -0.8289 | -0.8289 | 0.5677 | 0.8291 | 0.2936 | -- | 8.13 | 5,615,030.00 | -42.88 | -40.06 | -66.66 | -49.74 | -- | -- | -146.02 | -415.41 | -- | -- | 0.00 | -- | 777.23 | -- | 15.64 | -- | -- | -- |
| Lipigon Pharmaceuticals AB | 16.41m | -12.13m | 34.96m | -- | -- | 1.23 | -- | 2.13 | -0.4662 | -0.4662 | 0.3201 | 0.225 | 0.7388 | -- | 14.81 | -- | -54.60 | -314.67 | -75.05 | -426.49 | -- | -- | -73.91 | -488.14 | -- | -- | 0.00 | -- | -- | 444.44 | 67.83 | -- | -- | -- |
| Diagonal Bio AB | 23.00k | -11.68m | 39.82m | 4.00 | -- | 0.1819 | -- | 1,731.47 | -0.1982 | -0.1982 | 0.0004 | 0.3221 | 0.0007 | -- | 2.00 | 5,750.00 | -37.35 | -- | -44.49 | -- | -41,604.35 | -- | -50,769.57 | -- | 0.5105 | -104.20 | -- | -- | -88.67 | -- | 27.75 | -- | -- | -- |
| Modus Therapeutics Holding AB | 0.00 | -17.90m | 41.15m | 2.00 | -- | 2.33 | -- | -- | -1.04 | -1.04 | 0.00 | 0.492 | 0.00 | -- | -- | 0.00 | -114.31 | -141.06 | -237.09 | -278.44 | -- | -- | -- | -- | -- | -10.96 | 0.00 | -- | -- | -- | 2.31 | -- | -- | -- |
| NextCell Pharma AB | 12.45m | -39.37m | 42.46m | -- | -- | 0.7604 | -- | 3.41 | -1.15 | -1.15 | 0.3621 | 1.62 | 0.1406 | 14.06 | 7.20 | -- | -44.45 | -34.92 | -50.09 | -37.06 | 12.04 | -68.21 | -316.25 | -538.60 | 4.36 | -- | 0.00 | -- | 80.96 | 72.85 | -15.21 | -- | -- | -- |
| Gabather AB | 0.00 | -9.44m | 43.25m | -- | -- | 72.24 | -- | -- | -0.652 | -0.652 | 0.00 | 0.0331 | 0.00 | -- | -- | -- | -133.71 | -56.57 | -480.99 | -67.36 | -- | -- | -- | -17,298,800.00 | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- |
| Veg of Lund AB (publ) | 4.82m | -19.91m | 44.77m | 7.00 | -- | 1.07 | -- | 9.30 | -0.7328 | -0.7328 | 0.1519 | 1.01 | 0.1337 | 13.74 | 14.40 | 688,000.00 | -55.27 | -129.03 | -82.56 | -209.20 | -384.61 | -781.09 | -413.50 | -923.73 | 0.1256 | -12.90 | 0.1405 | -- | 89.57 | 39.87 | 56.02 | -- | -12.47 | -- |
| Oncozenge AB | 0.00 | -15.90m | 45.33m | -- | -- | 2.43 | -- | -- | -1.36 | -1.36 | 0.00 | 1.59 | 0.00 | -- | -- | -- | -55.57 | -- | -60.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 65.91 | -- | -- | -- |
